Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems

Advanced Prostate Cancer

Advanced-stage prostate cancer patients experience 20-year survival rates with surgery

Long-term survival rates for patients with advanced prostate cancer suggest they can be good candidates for surgery, Mayo Clinic researchers have found. Their study found a 20-year survival rate for 80 percent of patients diagnosed with cancer that has potentially spread beyond the prostate, known as cT3 prostate cancer, and treated with radical prostatectomy,… Advanced-stage prostate cancer patients experience 20-year survival rates with surgery   



Antifungal drug delays need for chemo in advanced prostate cancer

The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease. Details of the finding, from a clinical trial led by Johns Hopkins experts, are scheduled for presentation on Saturday, June 4 at the 2011 American… Antifungal drug delays need for chemo in advanced prostate cancer   



UT Southwestern scientists discover new pathway to potential therapies for advanced prostate cancer

UT Southwestern Medical Center researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than was thought previously.

While testosterone is generally known to stimulate the growth of the disease, advanced prostate cancer that is resistant to standard hormonal therapy actually… UT Southwestern scientists discover new pathway to potential therapies for advanced prostate cancer   



New treatment option for advanced prostate cancer

Prostate cancer that has become resistant to hormone treatment and that does not respond to radiation or chemotherapy requires new methods of treatment. By attacking stem cell-like cells in prostate cancer, researchers at Lund University are working on a project to develop a new treatment option.

A successful interdisciplinary project is underway between two… New treatment option for advanced prostate cancer   



Zytiga, Prostate Cancer Drug, Improves Survival: Study

Johnson & Johnson’s drug for advanced prostate cancer, Zytiga, was deemed so beneficial in patients who had not received chemotherapy that safety advisors said those in the placebo group of a late stage trial should be offered the treatment, the company said

The unanimous recommendation by independent safety monitors was based on improvements in… Zytiga, Prostate Cancer Drug, Improves Survival: Study   



For advanced prostate cancer, new drug slows disease

A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results.

The study is the first randomized… For advanced prostate cancer, new drug slows disease   



Drug slows advanced prostate cancer: study

A drug that is already approved for prostate cancer has been shown to slow the spread of advanced forms of the disease for the first time, according to research released Saturday.

Zytiga, made by Johnson and Johnson, is being tested in a randomized phase III trial involving 1,088 men with prostate cancer at 151… Drug slows advanced prostate cancer: study   



What would happen without PSA testing?

A new analysis has found that doing away with PSA (prostate specific antigen) testing for prostate cancer would likely cause three times as many men to develop advanced disease that has spread to other parts of the body before being diagnosed. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society,… What would happen without PSA testing?   



end-stage renal disease12 - osteoporosis1 - investigational aurora kinase1 - embryogenesis1 - low blood potassium1 - diagnostic test2 - pcnl1 - castration-resistant prostate cancer5 - congenital malformations1 - renal arteries2 - high glucose1 - streptococcal infection1 - regional lymph nodes1 - prostate-related diseases1 - invasive treatment1 - radical prostatectomy9 - hepatolenticular degeneration1 - conners parent rating scale-revised1 - apple shape1 - carcinoid1 - mitotane1 - inherited kidney disease2 - prostate cancer survival1 - dehydration1 - cancerous tissue1 - urinary sulfate2 - c-reactive protein1 - voiding symptoms1 - ohip1 - nephronophthisis1 -